BEDMINSTER, N.J., Nov. 22 /PRNewswire-FirstCall/ -- Bioject Medical Technologies Inc. , a leading developer of needle-free drug delivery systems, announced today that it has received a Small Business Innovation Research (SBIR) contract from the Centers of Disease Control and Prevention (CDC) to build and test a prototype of a needle-free single-dose injection delivery system featuring auto-disabling disposable-cartridges and a jet injector device.
Designed to be sturdy and economical for use in developing country immunization programs, the jet injector system will also be suitable for doctor’s offices in developed countries. The system consists of a durable, manually-powered, mechanical device, requiring no electricity, batteries, or other external supply of power. Its sterile cartridge, once filled and used for a single injection, cannot be refilled and is disposed safely without exposing health workers to needlestick “sharps” injuries.
A similar proof-of-concept jet injector was evaluated by focus groups of health care workers in Africa, whose feedback contributed to the design of the new device. For the purposes of this SBIR contract, Bioject plans to build and test prototypes for safely and effectively delivering subcutaneous, intramuscular and intradermal injections of vaccines and potentially other liquid pharmaceuticals.
“We are pleased to have received a contract from the CDC for the development of an immunization device with an auto-disabling needle free cartridge,” said Jim O’Shea, Chairman, President and CEO of Bioject. “The initial prototypes to be developed under this contract will be used to conduct in vitro and in vivo studies that will demonstrate that our new needle-free technology with non-reusable cartridges can meet safely the challenges of global immunization.”
About Bioject
Bioject Medical Technologies Inc., based in Bedminster, New Jersey, with operations in Portland, Oregon, is an innovative developer and manufacturer of needle-free drug delivery systems. Needle-free injection works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid that penetrates the skin and deposits vaccine in the tissue beneath. Bioject is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies.
For more information about Bioject, visit www.bioject.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks, uncertainties and other factors include, without limitation, the risk that the products will not be accepted by the market, uncertainties related to the time required for the Company to complete research and development, obtain necessary clinical data and government clearances, the risk that the Company may be unable to produce our products at a unit cost necessary for the products to be competitive in the market and the risk that the Company may be unable to comply with the extensive government regulations applicable to Bioject’s business. Readers of this press release are referred to the Company’s filings with the Securities and Exchange Commission, including the Company’s reports on Form 10-K and Forms 10-Q for further discussions of factors that could affect the Company’s business and its future results. Forward-Looking statements are based on the estimates and opinions of management on the date the statements are made. The Company assumes no obligation to update forward-looking statements if conditions or management’s estimates or opinions should change.
Bioject Medical Technologies Inc.
CONTACT: John Gandolfo, Chief Financial Officer of Bioject MedicalTechnologies Inc., +1-908-470-2800, ext. 5102, or jgandolfo@bioject.com; orJohn Baldissera of BPC Financial Marketing, 1-800-368-1217, for BiojectMedical Technologies Inc.
Web site: http://www.bioject.com/
